Latest Articles
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - EIN News
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR EIN News
Published: Jan. 21, 2025, 10:38 a.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - ABN Newswire
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR ABN Newswire
Published: Jan. 21, 2025, 12:38 a.m.
Management of Diaphragmatic Central Tendon Plays an Important Role in the Surgical Treatment of Catamenial Pneumothorax: A Case Report - Cureus
Management of Diaphragmatic Central Tendon Plays an Important Role in the Surgical Treatment of Catamenial Pneumothorax: A Case Report Cureus
Published: Jan. 20, 2025, 9:41 p.m.
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment - Femtech Insider
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment Femtech Insider
Published: Jan. 20, 2025, 10:56 a.m.
Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment - beQuoted
Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment beQuoted
Published: Jan. 20, 2025, 8:21 a.m.
GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment - DirectorsTalk Interviews
GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment DirectorsTalk Interviews
Published: Jan. 20, 2025, 7:28 a.m.
GSK’s Jemperli Gains Expanded EU Approval for Broader Endometrial Cancer Treatment - TipRanks
GSK’s Jemperli Gains Expanded EU Approval for Broader Endometrial Cancer Treatment TipRanks
Published: Jan. 20, 2025, 7:19 a.m.
Untreated painful periods can cost economy up to $14.2 billion per year - Women's Agenda
Untreated painful periods can cost economy up to $14.2 billion per year Women's Agenda
Published: Jan. 20, 2025, 1:08 a.m.
A cRGD-modified liposome for targeted delivery of artesunate to inhibit angiogenesis in endometriosis.
Currently, hormonal therapy for endometriosis faces challenges in achieving a balance between treatment and preserving the chance of pregnancy. Therefore, the development of non-hormonal therapy holds significant clinical importance. Angiogenesis …
Published: Jan. 20, 2025, midnight
Understanding Deep Endometriosis: From Molecular to Neuropsychiatry Dimension.
Endometriosis is a widely spread disease that affects about 8% of the world's female population. This condition may be described as a spread of endometrial tissue apart from the uterine …
Published: Jan. 20, 2025, midnight
Link copied to clipboard!